

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Mail Stop Patent Application
commissioner for Patents
Commissioner for Patents
Alexandria, VA 22313-1450

under 37 CFR 1.53(b) of:

Transmitted herewith for filing is the patent application

January 26, 2

Date of Deposit

L. L. L.

AVENTIS DOCKET NO.: ST01033 US CNT

INVENTORS: Antony Bigot, et al

TITLE:

USE OF 2-AMINO-THIAZOLINE DERIVATIVES AS INHIBITORS OF INDUCIBLE NO-SYNTHASE I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 26, 2004

Date of Deposit

Signature

EL964822233US

Express Mail No.

22387 U.S.PTO 10/764853

APPLICATION ELEMENTS

AFF	LICA	HON ELEWENTS								
1.	\boxtimes	*Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing)								
2.		Specification (preferred arrangement set forth below) - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure	Total Pages	23						
3.		Drawing(s) (35 U.S.C. 113)	Total Sheets							
4.	Oath a.	or Declaration Newly executed (original or copy)	Total Pages	2						
	b.	Copy from a prior application (37 CFR § 1.63(d))								
		i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the price application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).								
5.	Powe a. b.	er of Attorney Copy of executed document Copy from a prior application (37 CFR § 1	Total Pages	1						
6.		Microfiche Computer Program (Appendix)								

Page 2 Nucleotide and/or Amino Acid Sequence Submission 7. (if applicable, all necessary) Computer Readable Copy Paper Copy (identical to computer copy) b. Statement verifying identity of above copies C. If a CONTINUING Application, check appropriate box, and supply the requisite information: Divisional ○ Continuation Continuation-in-part of prior application no: 10/291,084, filed November 8, 2002, Examiner _____, Group/Art Unit (The cross reference has been/will be inserted on page one of the specification). This application claims the benefit of U.S. Provisional Application No. 60/352,797, filed January 30, 2002. (The cross reference has been/will be inserted on page one of the specification). Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the prior application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. **ACCOMPANYING APPLICATION PARTS** 7. Assignment Papers (cover sheet & document(s)) 8. 37 CFR §3.73(b) Statement (when there is an assignee) Verified English Translation Document (if applicable) 9. 10. Information Disclosure Copies of IDS Citations Statement (IDS)/PTO-1449 11. **Preliminary Amendment** 12. Return Receipt Postcard (MPEP 503) (Should be specifically itemized) *Small Entity Statement(s) Statement filed in prior application, 13. Status still proper and desired (PTO/SB/09-12) Certified Copy of Priority Document(s) 14. (if foreign priority is claimed) Application Data Sheet (3 pgs.) Other: **CORRESPONDENCE ADDRESS** Customer Number or Bar Code Label 005487 (Insert Customer No. or Attach bar code label here) . Bolcsak, Reg. No. 39,912 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-5922
Telefax (908) 231-2626
Aventis Docket No. ST01033 US CNT

Application Transmittal Letter

ST01033 US CNT

Approved for use through 04/30/2003. OMB 0651-0032
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Attorney Docket No.

Complete if Known FEE TRANSMITTAL **Application Number** Not Yet Assigned Filing Date C ncurrently Filed Herewith for FY 2004 Ant ny Bigot, et al First Named Inventor Patent fees are subject to annual revision. **Examiner Name** Applicant claims small entity status. See 37 CFR 1.27 Group / Art Unit

(\$) 770.00

METHOD OF PAYMENT (check all that apply)						apply)	FEE CALCULATION (continued)					
Check Credit Card Money Other None							3. Al	ODITIO	NAL F	EES		
Order Deposit Account								ntity	Small E	ntity		
Deposit							Fee Code	Fee (\$)	Fee Code	Fee (\$)		
Number Deposit	lumber 10-1702							(0)	Code	(4)	Fee Description	Fee Paid
Account Aventis Pharmaceuticals Inc.								120	2054	C.F.	Course lets filips to a costs	
Name Th C mmissioner is authorized to: (check all that apply)							1051 1052	130	2051	65	Surcharge - late filing fee or oath Surcharge - late provisional filing fee or	
Charge fee(s) indicated below Credit any overpayments								50 130	2052 1053	25 130	cover sheet Non-English Specification	
Charge any additional fee(s) during the pendency of this application								2,520	1812	2,520	For filing a request for reexamination	
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account								920*	1804	920*	Requesting publication of SIR prior to Examiner action	
FEE CALCULATION								1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1. BASIC FILING FEE								110	2251	55	Extension for reply within first month	
	Fee	Fee	II Entity Fee	Fee De	escription	Fee Paid	1252	420	2252	205	Extension for reply within second month	
	(\$) 770	2001	(\$) 375	Utility f	iling fee	770	1253	950	2253	465	Extension for reply within third month	
f	340	2002	165	•	filing Fee		1254	1,480	2254	725	Extension for reply within fourth month	-
1003	530	2003	260	Plant fi	iling fee	-	1255	2,010	2255	985	Extension for reply within fifth month	
1004	770	2004	375	Reissu	e filing fee		1401	330	2401	160	Notice of Appeal	
1005	160	2005	80	Provisi	onal filing fee		1402	330	2402	160	Filing a brief in support of an appeal	
	•	SU	BTOT	AL (1)	(\$) 770.00)	1403	290	2403	140	Request for oral hearing	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE							1451	1,510	1451	1,510	Petition to institute a public use proceeding	
				Extra	Fee from	Fee	1452	110	2452	55	Petition to revive - unavoidable	
				Claims	below	Paid						
Total Claims	s 8		-20**=	0	x 18	= 0	1453	1,330	2453	650	Petition to revive - unintentional	
Independent 2 - 3**= 0 x 86 = 0							1501	1,330	2501	650	Utility issue fee (or reissue)	
Claims							1502 1503	480	2502	235	Design issue fee	
Multiple Dependent 0 = 0								640	2503	315	Plant issue fee	
Large Entit	tv I	Smal	ll Entity				1460 1807	130 50	1460 1807	130 50	Petitions to the Commissioner Petitions related to provisional	
Fee F	ee	Fee	Fee					00	1007	00	applications	
Code (1202	(\$) 18	Code 2202	(\$) 9		escription in excess of 20		1806	180	1806	180	Submission of Information Disclosure	
1201	86	2201	42	Indepe	Independent claims in excess of 3			40	8021	40	Stmt Recording each patent assignment per property (times number of properties)	
1203 2	290	2203	140	Multiple	Multiple dependent claim, if not			770	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1204	86	2204	42	**Reiss	sue independent is over original p	1810	770	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))		
1205 18 2205 9 **Reissue claims in excess of 20 and over original patent							1801	770	2801	375	Request for Continued Examination (RCE)	
							1802	900	1802	900	Request for expedited examination of a design application	
SUBTOTAL (2) (\$) 0.00								Other fee (specify)				
**or number previously paid, if greater; For Reissues, see above						bove	*Reduced by Basic Filing Fee Paid			e Paid	SUBTOTAL (3) (\$)	

SUBMITTED BY Complete (If applicable) Registration No. Name (Print/Type) James W. Bolcsak, Reg. No. 39,912 39.912 Telephone (908) 231-5922 (Attorney/Agent) W.15 L 2604 Signature Date

> WARNING: Information on this form may bec m public. Credit card inf rmation should n t be included n this form. Provide credit card inf rmation and authorizati n on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Alexandria, VA 22313. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

TOTAL AMOUNT OF PAYMENT